Financials
CSCI Cosciens Biopharma, Inc. (TOR)
-
- Last: 3.290
- Change: +0.41 (+14.24%)
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|
| Revenues | 13.13 M | 9.64 M | 7.34 M | 6.59 M |
| Gain (Loss) on Sale of Assets | 283.58 K | 0.00 | N/A | N/A |
| Gain (Loss) on Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Fees and Other Income | 200.01 K | 453.49 K | 1.14 M | 269.55 K |
| Other Revenues | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Revenues | 13.13 M | 9.64 M | 7.34 M | 6.59 M |
| Cost of Revenues | 4.45 M | 3.73 M | 204.39 K | 112.84 K |
| Gross Profit | 6.48 M | 3.97 M | 6.96 M | 6.30 M |
| Selling General and Admin. Expenses | 14.31 M | 7.46 M | 10.54 M | 8.93 M |
| Provision for Bad Debts | 2.71 M | 166.14 K | 546.05 K | 1.11 M |
| R&D Expenses | 11.38 M | 2.75 M | 16.28 M | 8.24 M |
| Depreciation and Amortization | 2.20 M | 1.95 M | 175.75 K | 181.79 K |
| Amortization of Goodwill and Intangibles | 221.93 K | 2.70 K | 6.51 K | 20.06 K |
| Other Operating Expense (Income) | -19.21 M | -6.25 M | -20.02 M | -10.87 M |
| Total Operating Expenses | 18.77 M | 11.19 M | 10.74 M | 9.04 M |
| Operating Income | -19.21 M | -6.25 M | -20.02 M | -10.87 M |
| Interest Expense | 176.73 K | 183.56 K | 3.91 K | 26.33 K |
| Interest and Investment Income | 604.15 K | 79.63 K | 0.00 | 0.00 |
| Net Interest Expense | 176.73 K | 183.56 K | 3.91 K | 26.33 K |
| Currency Exchange Gains (Loss) | -290.43 K | 211.90 K | -1.14 M | -964.12 K |
| Net Other Income (Expense) | 200.01 K | 453.49 K | 1.14 M | 269.55 K |
| EBT Including Unusual Items | -18.41 M | -5.71 M | -18.87 M | -10.60 M |
| Merger and Restructuring Charges | N/A | 0.00 | N/A | 0.00 |
| Impairment of Goodwill | 0.00 | 9.23 K | 0.00 | 789.47 K |
| Asset Writedown | 34.36 M | -985.27 K | -15.62 K | -824.96 K |
| Insurance Settlements | 0.00 | 0.00 | 0.00 | 0.00 |
| Legal Settlements | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Tax Expense | 115.08 K | -1.19 M | 0.00 | -136.66 K |
| Minority Interest in Earnings | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings from Continuing Operations | -20.97 M | -4.70 M | -29.59 M | -10.49 M |
| Earnings of Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Item and Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -20.97 M | -4.70 M | -29.59 M | -10.49 M |
| Preferred Dividends and Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income to Common Incl. Extra Items | -20.97 M | -4.70 M | -29.59 M | -10.49 M |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 |
Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement.
Canadian Mutual Fund and ETF data provided by Fundata Canada Inc. Press Releases provided by Comtex News Network.